Search

Search Constraints

You searched for: Author/Creator Polson, Andrew G.

Search Results

1. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs. Issue 23 (1st December 2017)

3. Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. (24th August 2019)

4. Intra-tissue catabolite characterization is a missing link in discovery of ADCs. Issue 1 (January 2019)

5. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response. Issue 1 (1st January 2021)

6. Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. Issue 8 (17th November 2018)

7. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. Issue 5 (4th July 2018)

8. Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. Issue 3 (17th January 2023)